An understanding of the potential immunogenicity risk of your therapeutic candidate is a key part of pre-clinical development. While human primary cell assays can provide vital data to help support this assessment, the design and qualification of such human in vitro assays is key to generating high quality, reliable data to support regulatory filings. Here we discuss how a panel of healthy donors can be pre-qualified for specific assays and how this donor panel can then be used in studies to assess the immunogenicity risk of therapeutics.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center